Global Gastric Cancer Treatment Market Overview:
As per MRFR analysis, the Gastric Cancer Treatment Market Size was estimated at 2.55 (USD Billion) in 2022. The Gastric Cancer Treatment Market is expected to grow from 2.81 (USD Billion) in 2023 to 6.8 (USD Billion) by 2032. The Gastric Cancer Treatment Market CAGR (growth rate) is expected to be around 10.31% during the forecast period (2024 - 2032).
Key Gastric Cancer Treatment Market Trends Highlighted
Advancements in Treatment Modalities: Recent years have witnessed significant progress in gastric cancer treatment, with the emergence of targeted therapies and immunotherapies.
Targeted therapies precisely target specific molecules or pathways involved in cancer growth, while immunotherapies harness the patient's immune system to fight the disease.
Shift Towards Early Detection and Minimally Invasive Surgeries: Early detection and subsequent minimally invasive surgical interventions play a crucial role in improving patient outcomes.
Endoscopic techniques, such as endoscopic mucosal resection and endoscopic submucosal dissection, allow for the removal of precancerous lesions and early-stage cancers with minimal damage to surrounding tissues.
Personalized Medicine and Biomarkers: Advances in genomics and molecular profiling have paved the way for personalized medicine in gastric cancer treatment.
By identifying specific genetic markers or biomarkers, clinicians can tailor treatments to the individual patient's unique molecular profile, increasing treatment efficacy and reducing side effects.
Growing Focus on Palliative Care and End-of-Life Support: With the increasing prevalence of advanced gastric cancer, managing symptoms and improving the quality of life for patients and their families has become paramount.
Palliative care interventions are being widely adopted to provide holistic support, addressing physical, emotional, and practical aspects of the disease.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Gastric Cancer Treatment Market Drivers
Rising Prevalence of Gastric Cancer
Gastric cancer is the fifth most frequently diagnosed cancer and the fifth leading cause of cancer-related death globally, with approximately 1 million new cases diagnosed each year.
Gastric cancer is the most common cancer type in East Asia, Eastern Europe, and South America, but it is also present in other parts of the world.
The high and rising prevalence is a major growth driver for the gastric cancer treatment market. The incidence of gastric cancer has been rising due to multiple reasons, including the aging population, the adoption of Western lifestyles, and the increasing prevalence of Helicobacter pylori infection.
Helicobacter pylori is a type of bacteria that infects the stomach and is one of the biggest risk factors for the development of gastric cancer. Moreover, stomach cancer often complicates Helicobacter pylori infection.
Most importantly, the prevalence of Helicobacter pylori infection is highest in developing countries, where it is estimated to infect up to 80% of the population. The incidence of gastric cancer is rising, and it will continue to do so in the upcoming years, and the demand for gastric cancer treatments will follow suit.
Technological Advancements in Gastric Cancer Treatment
Another significant factor driving the expansion of the gastric cancer treatment market is the development of new and more effective treatments for this type of cancer.
In recent years, there have been many advances in the development of surgical techniques, chemotherapy regimens, and radiation therapy techniques for gastrointestinal cancers, which have made those treatments more effective.
As a result, the five-year survival rate for patients with localized gastric cancer has increased from 60% to 90% in recent years.
In addition, significant advancements in the development of gene-based treatments, such as HER2 inhibitors, have been made, and similar advancements are expected to be made in the future.
Increasing Awareness of Gastric Cancer
Another major driver of the growth of the gastric cancer treatment market is the increasing awareness of gastric cancer. In recent years, there has been a growing awareness of the symptoms of gastric cancer and the importance of early diagnosis and treatment.
This increased awareness is attributable to public health campaigns, the media, and the internet, among other things. The effect of this is that in the coming years, cases of gastric cancer will become even more widespread, and the demand for gastric cancer treatments will correspondingly increase.
Gastric Cancer Treatment Market Segment Insights:
Gastric Cancer Treatment Market Treatment Type Insights
The Gastric Cancer Treatment Market is segmented by Treatment Type into Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy, and Immunotherapy. Surgery is the primary treatment for gastric cancer.
The type of surgery performed depends on the stage of the cancer and the patient's overall health. The most common type of surgery is gastrectomy, which involves removing part or all of the stomach.
Other types of surgery include esophagectomy, which involves removing part or all of the esophagus, and pancreatectomy, which involves removing part or all of the pancreas.
Chemotherapy is a type of drug therapy that uses cytotoxic drugs to kill cancer cells. Chemotherapy can be given orally or intravenously. The most common chemotherapy drugs used to treat gastric cancer include 5-fluorouracil, cisplatin, and oxaliplatin.
Radiation therapy uses high-energy beams of radiation to kill cancer cells. Radiation therapy can be given externally or internally. External radiation therapy is delivered from a machine outside the body, while internal radiation therapy is delivered from radioactive implants placed inside the body.
Targeted Therapy: Targeted therapy is a type of drug therapy that uses drugs that target specific molecules or proteins involved in the growth and spread of cancer cells. The most common targeted therapy drugs used to treat gastric cancer include trastuzumab, bevacizumab, and ramucirumab.
Immunotherapy is a type of treatment that uses the patient's own immune system to fight cancer. Immunotherapy drugs work by boosting the immune system's ability to recognize and kill cancer cells.
The growth of the market is attributed to the increasing incidence of gastric cancer, the development of new and more effective treatment options, and the growing adoption of minimally invasive surgical techniques.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Gastric Cancer Treatment Market Route of Administration Insights
The Gastric Cancer Treatment Market is segmented based on Route of Administration into Intravenous, Oral, and Subcutaneous. Among these, the Intravenous segment held the largest market share in 2023 and is expected to continue its dominance throughout the forecast period.
The Oral segment is projected to grow at a CAGR of 10.1% during the forecast period, driven by the rising prevalence of gastric cancer and the increasing availability of oral formulations of chemotherapeutics and targeted therapies.
The Subcutaneous segment is also expected to experience steady growth during the forecast period, owing to the convenience and ease of administration of subcutaneous injections compared to intravenous infusions.
Gastric Cancer Treatment Market Side Effects Management Insights
The Side Effects Management segment of the Gastric Cancer Treatment Market is projected to reach USD 1.2 billion by 2024, exhibiting a CAGR of 10.31% during the forecast period.
The rising prevalence of gastric cancer, coupled with the increasing demand for effective side effects management solutions, is driving market growth.
Anti-nausea medications, pain management medications, and supportive care measures are the key product categories within this segment. Anti-nausea medications are widely used to prevent and treat nausea and vomiting associated with chemotherapy and radiation therapy.
The growing adoption of 5-HT3 receptor antagonists and NK-1 receptor antagonists is contributing to the growth of this category. Pain management medications, such as opioids and non-steroidal anti-inflammatory drugs (NSAIDs), are essential for managing pain caused by gastric cancer and its treatment.
The increasing use of targeted therapies and immunotherapy, which can cause unique side effects, is also fueling the demand for pain management medications.
Supportive care measures, including nutritional support, hydration therapy, and psychological support, play a crucial role in improving the quality of life for gastric cancer patients.
The rising focus on patient-centered care and the growing awareness of the importance of supportive care are driving the growth of this category.
The Gastric Cancer Treatment Market is expected to continue to expand in the coming years, fueled by the increasing prevalence of gastric cancer and the growing demand for effective side effects management solutions.
Gastric Cancer Treatment Market Disease Stage Insights
Early-stage gastric cancer, limited to the mucosa or submucosa, accounted for around 55% of the Gastric Cancer Treatment Market revenue in 2023.
The high prevalence of early-stage gastric cancer can be attributed to increased screening and early detection initiatives, particularly in developed regions such as North America and Europe.
Advanced-stage gastric cancer, which has spread to regional lymph nodes or distant organs, represented the remaining 45% of the market.
The Gastric Cancer Treatment Market for advanced-stage gastric cancer is expected to witness a higher growth rate compared to early-stage gastric cancer due to the increasing incidence of advanced-stage disease and the availability of more advanced treatment options.
Gastric Cancer Treatment Market Molecular Biomarkers Insights
The Gastric Cancer Treatment Market is segmented by Molecular Biomarkers into HER2-Positive Gastric Cancer, MSI-High Gastric Cancer, and EGFR-Positive Gastric Cancer. The HER2-Positive Gastric Cancer segment held the largest market share in 2023, accounting for over 40% of the global market.
The market for HER2-Positive Gastric Cancer is expected to grow at a CAGR of 12.5% during the forecast period, reaching a value of USD 3.2 billion by 2032.
The growth of this segment is attributed to the increasing prevalence of HER2-positive gastric cancer and the availability of effective targeted therapies, such as trastuzumab and pertuzumab.
The MSI-High Gastric Cancer segment is expected to grow at a CAGR of 14.2% during the forecast period, reaching a value of USD 2.5 billion by 2032. The growth of this segment is attributed to the increasing awareness of MSI-high gastric cancer and the development of novel immunotherapies, such as pembrolizumab and nivolumab.
The EGFR-Positive Gastric Cancer segment is expected to grow at a CAGR of 10.8% during the forecast period, reaching a value of USD 1.8 billion by 2032.
The growth of this segment is attributed to the increasing prevalence of EGFR-positive gastric cancer and the availability of effective targeted therapies, such as cetuximab and panitumumab.
Gastric Cancer Treatment Market Regional Insights
The Gastric Cancer Treatment Market is segmented into North America, Europe, APAC, South America, and MEA. North America held the largest market share in 2023, owing to the high prevalence of gastric cancer and the presence of advanced healthcare infrastructure.
Europe is expected to be the second-largest market, followed by APAC. The APAC region is expected to witness the highest growth rate during the forecast period due to the increasing incidence of gastric cancer and the growing adoption of advanced treatment modalities.
South America and MEA are expected to account for a relatively smaller share of the global market. The key factors driving the growth of the Gastric Cancer Treatment Market include the rising incidence of gastric cancer, the increasing adoption of advanced treatment modalities, and the growing awareness of gastric cancer screening and early detection programs.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Gastric Cancer Treatment Market Key Players and Competitive Insights:
The Gastric Cancer Treatment Market is witnessing an increasing number of major players who are actively pursuing strategic decisions like mergers and acquisitions, partnerships and research and development to fortify their foothold in the market.
At the same time, high levels of investment in research and development activities have seen the market in a state of competition where novel and innovative products see high levels of adoption in existing clinical settings.
In the Gastric Cancer Treatment Market, the level of consolidation between established entities and entrants has been noted to be on the rise.
Given the stated scenario, it is important to note that the leading Gastric Cancer Treatment Market are delivering high performance and innovation with a strong focus on personalized and precision treatment options which have shown to deliver superior patient outcomes accompanied by reduced side effects.
As for the current scenario, the development pipeline is looking promising with a large number of products coming up for clearance and launch.
Roche is one of the leading players in the Gastric Cancer Treatment Market, where the company has boasted of a powerhouse product – Herceptin – which belongs to the category of targeted therapy which has demonstrated the potential to impact the prognosis of thousands of patients possessing the HER2 receptor gene.
On the other hand, the company’s vast experience in research and development finds reflection in its intent of expanding the number of indications of its existing therapies and also in its pipelines which comprises of majority of new and novel treatment modalities.
Alongside, the company’s superior network has also demonstrated its willingness to export products from its basket of products to nations where the demand has expanded.
AstraZeneca is another major entrant in the Gastric Cancer Treatment Market where the company’s position in the oncology market is quite strong.
The company's venture, Imfinzi – an immunotherapy drug – has shown great promise when it comes to treating patients with advanced gastric and esophageal cancer.
Going further, AstraZeneca is further increasing its pipeline and combination therapy options by combining Imfinz with other medications. AstraZeneca has a promising future in the Gastric Cancer Treatment Market.
Key Companies in the Gastric Cancer Treatment Market Include:
- Eli Lilly and Company
- Johnson Johnson
- Roche
- Celgene Corporation
- AstraZeneca
- Gilead Sciences
- Sanofi
- Bristol-Myers Squibb
- Pfizer
- Bayer
- Novartis
- AbbVie
- Merck Co
- Amgen
Gastric Cancer Treatment Market Developments
The increasing prevalence of gastric cancer, coupled with the rising demand for advanced treatment options, is driving market growth.
Furthermore, the introduction of novel therapies and the expansion of healthcare infrastructure in emerging economies are contributing to the market's expansion.
Key recent developments include the approval of new drugs such as pembrolizumab and nivolumab for the treatment of advanced gastric cancer, as well as the ongoing research and development of targeted therapies and immunotherapies.
Gastric Cancer Treatment Market Segmentation Insights
- Gastric Cancer Treatment Market Treatment Type Outlook
- Surgery
- Chemotherapy
- Radiation Therapy
- Targeted Therapy
- Immunotherapy
- Gastric Cancer Treatment Market Route of Administration Outlook
- Intravenous
- Oral
- Subcutaneous
- Gastric Cancer Treatment Market Side Effects Management Outlook
- Anti-Nausea Medications
- Pain Management Medications
- Supportive Care Measures
- Gastric Cancer Treatment Market Disease Stage Outlook
- Early-Stage Gastric Cancer
- Advanced-Stage Gastric Cancer
- Gastric Cancer Treatment Market Molecular Biomarkers Outlook
- HER2-Positive Gastric Cancer
- MSI-High Gastric Cancer
- EGFR-Positive Gastric Cancer
- Gastric Cancer Treatment Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
| Report Attribute/Metric |
Details |
| Market Size 2022 |
2.55(USD Billion) |
| Market Size 2023 |
2.81(USD Billion) |
| Market Size 2032 |
6.8(USD Billion) |
| Compound Annual Growth Rate (CAGR) |
10.31% (2024 - 2032) |
| Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year |
2023 |
| Market Forecast Period |
2024 - 2032 |
| Historical Data |
2019 - 2023 |
| Market Forecast Units |
USD Billion |
| Key Companies Profiled |
Eli Lilly and Company, Johnson Johnson, Roche, Celgene Corporation, AstraZeneca, Gilead Sciences, Sanofi, Bristol-Myers Squibb, Pfizer, Bayer, Novartis, AbbVie, Merck Co, Amgen |
| Segments Covered |
Treatment Type, Route of Administration, Side Effects Management, Disease Stage, Molecular Biomarkers, Regional |
| Key Market Opportunities |
Global Endoscopic Mucosal Resection Surgery Chemotherapy Targeted Therapy Immunotherapy |
| Key Market Dynamics |
Expanding prevalence of gastric cancer Rising demand for targeted therapies Advancements in surgical techniques Availability of emerging therapies Growing adoption of minimally invasive procedures |
| Countries Covered |
North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Gastric Cancer Treatment Market was valued at USD 2.81 billion in 2023 and is projected to reach USD 6.8 billion by 2032, exhibiting a CAGR of 10.31% during the forecast period.
North America dominated the Gastric Cancer Treatment Market, accounting for a significant share of the market in 2023 and is projected to maintain its dominance throughout the forecast period.
The increasing prevalence of gastric cancer, advancements in treatment modalities, and government initiatives aimed at improving cancer care are the key factors driving the growth of the Gastric Cancer Treatment Market.
The major applications of Gastric Cancer Treatment include surgery, chemotherapy, radiation therapy, targeted therapy, and immunotherapy.
Key competitors in the Gastric Cancer Treatment Market include Merck Co., Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Eli Lilly and Company, and Pfizer Inc., among others.
The Gastric Cancer Treatment Market is expected to grow at a CAGR of 10.31% from 2024 to 2032.
Challenges faced by the Gastric Cancer Treatment Market include the high cost of treatment, limited access to healthcare facilities in developing countries, and side effects associated with treatment.
What are the opportunities for growth in the Gastric Cancer Treatment Market?
Key trends in the Gastric Cancer Treatment Market include the shift towards personalized medicine, the emergence of minimally invasive techniques, and the use of artificial intelligence in diagnosis and treatment.
The COVID-19 pandemic had a significant impact on the Gastric Cancer Treatment Market, leading to disruptions in healthcare services, delays in diagnosis and treatment, and increased mortality rates.
